Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirzepatide (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SURPASS J-mono
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 01 Jan 2024 Results of exploratory subgroup analysis assessing the HbA1c body weight and safety outcomes in patients with baseline HbA1c of less than equal to 8.5 percent and greater than 8.5 percent after 52 weeks of treatment with tirzepatide 5, 10 or 15 mg or dulaglutide 0.75 mg, published in the Diabetes, Obesity and Metabolism.
  • 16 Oct 2023 Results of exploratory post hoc subgroup analysis for the DTSQc overall treatment satisfaction score based on age, sex, baseline BMI and baseline glycated hemoglobin among patients with type 2 diabetes (T2D) after treatment with tirzepatide compared with dulaglutide published in the Diabetes Therapy.
  • 13 Sep 2023 Results of pooled analysis from SURPASS 1-5 and Japan-mono, and Japan-combo assessing pharmacokinetics, efficacy and safety published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top